DNA Damage Responses in Cancer Stem Cells: Implications for Cancer Therapeutic Strategies

Overview

Journal World J Biol Chem

Publisher Baishideng Publishing Group

Specialty Biochemistry

Date 2015 Sep 1

PMID 26322164

Citations 37

Authors

Qi-En Wang

Affiliations

Soon will be listed here.

Abstract

The identification of cancer stem cells (CSCs) that are responsible for tumor initiation, growth, metastasis, and therapeutic resistance might lead to a new thinking on cancer treatments. Similar to stem cells, CSCs also display high resistance to radiotherapy and chemotherapy with genotoxic agents. Thus, conventional therapy may shrink the tumor volume but cannot eliminate cancer. Eradiation of CSCs represents a novel therapeutic strategy. CSCs possess a highly efficient DNA damage response (DDR) system, which is considered as a contributor to the resistance of these cells from exposures to DNA damaging agents. Targeting of enhanced DDR in CSCs is thus proposed to facilitate the eradication of CSCs by conventional therapeutics. To achieve this aim, a better understanding of the cellular responses to DNA damage in CSCs is needed. In addition to the protein kinases and enzymes that are involved in DDR, other processes that affect the DDR including chromatin remodeling should also be explored.

Citing Articles

Cancer stem cells and tumor-associated macrophages as mates in tumor progression: mechanisms of crosstalk and advanced bioinformatic tools to dissect their phenotypes and interaction.

Verona F, Di Bella S, Schirano R, Manfredi C, Angeloro F, Bozzari G Front Immunol. 2025; 16:1529847.

PMID: 39981232 PMC: 11839637. DOI: 10.3389/fimmu.2025.1529847.

From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.

Gharib E, Robichaud G Int J Mol Sci. 2024; 25(17).

PMID: 39273409 PMC: 11395697. DOI: 10.3390/ijms25179463.

Concise review: breast cancer stems cells and their role in metastases.

Farahani M, Farjadmehr M, Atashi A, Momeni A, Behzadifard M Ann Med Surg (Lond). 2024; 86(9):5266-5275.

PMID: 39238997 PMC: 11374310. DOI: 10.1097/MS9.0000000000002270.

Investigation into the Neuroprotective and Therapeutic Potential of Plant-Derived Chk2 Inhibitors.

Kisielewska M, Filipski M, Sebastianka K, Karas D, Molik K, Choromanska A Int J Mol Sci. 2024; 25(14).

PMID: 39062967 PMC: 11277127. DOI: 10.3390/ijms25147725.

Boric Acid Alters the Expression of DNA Double Break Repair Genes in MCF-7-Derived Breast Cancer Stem Cells.

Semerci Sevimli T, Ghorbani A, Gakhiyeva F, Cevizlidere B, Sevimli M Biol Trace Elem Res. 2023; 202(9):3980-3987.

PMID: 38087035 DOI: 10.1007/s12011-023-03987-4.

References

Mocquet V, Laine J, Riedl T, Yajin Z, Lee M, Egly J . Sequential recruitment of the repair factors during NER: the role of XPG in initiating the resynthesis step. EMBO J. 2007; 27(1):155-67. PMC: 2206130. DOI: 10.1038/sj.emboj.7601948. View

Mu D, Park C, Matsunaga T, Hsu D, Reardon J, Sancar A . Reconstitution of human DNA repair excision nuclease in a highly defined system. J Biol Chem. 1995; 270(6):2415-8. DOI: 10.1074/jbc.270.6.2415. View

Lord C, Ashworth A . The DNA damage response and cancer therapy. Nature. 2012; 481(7381):287-94. DOI: 10.1038/nature10760. View

Johnsson A, Olsson C, Nygren O, Nilsson M, Seiving B, Cavallin-Stahl E . Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts. Cancer Chemother Pharmacol. 1995; 37(1-2):23-31. DOI: 10.1007/BF00685625. View

Magee J, Piskounova E, Morrison S . Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell. 2012; 21(3):283-96. PMC: 4504432. DOI: 10.1016/j.ccr.2012.03.003. View

Lim Y, Roberts T, Day B, Harding A, Kozlov S, Kijas A . A role for homologous recombination and abnormal cell-cycle progression in radioresistance of glioma-initiating cells. Mol Cancer Ther. 2012; 11(9):1863-72. DOI: 10.1158/1535-7163.MCT-11-1044. View

Mohrin M, Bourke E, Alexander D, Warr M, Barry-Holson K, Le Beau M . Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell. 2010; 7(2):174-85. PMC: 2924905. DOI: 10.1016/j.stem.2010.06.014. View

Pearl L, Schierz A, Ward S, Al-Lazikani B, Pearl F . Therapeutic opportunities within the DNA damage response. Nat Rev Cancer. 2015; 15(3):166-80. DOI: 10.1038/nrc3891. View

Zhang M, Behbod F, Atkinson R, Landis M, Kittrell F, Edwards D . Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res. 2008; 68(12):4674-82. PMC: 2459340. DOI: 10.1158/0008-5472.CAN-07-6353. View

10.

Clarke M, Dick J, Dirks P, Eaves C, Jamieson C, Jones D . Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006; 66(19):9339-44. DOI: 10.1158/0008-5472.CAN-06-3126. View

11.

Sale J, Lehmann A, Woodgate R . Y-family DNA polymerases and their role in tolerance of cellular DNA damage. Nat Rev Mol Cell Biol. 2012; 13(3):141-52. PMC: 3630503. DOI: 10.1038/nrm3289. View

12.

Darzynkiewicz Z, Traganos F, Wlodkowic D . Impaired DNA damage response--an Achilles' heel sensitizing cancer to chemotherapy and radiotherapy. Eur J Pharmacol. 2009; 625(1-3):143-50. PMC: 2783472. DOI: 10.1016/j.ejphar.2009.05.032. View

13.

Cheung-Ong K, Giaever G, Nislow C . DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology. Chem Biol. 2013; 20(5):648-59. DOI: 10.1016/j.chembiol.2013.04.007. View

14.

Stewart J, Shaw P, Gedye C, Bernardini M, Neel B, Ailles L . Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci U S A. 2011; 108(16):6468-73. PMC: 3081039. DOI: 10.1073/pnas.1005529108. View

15.

Shiomi N, Mori M, Tsuji H, Imai T, Inoue H, Tateishi S . Human RAD18 is involved in S phase-specific single-strand break repair without PCNA monoubiquitination. Nucleic Acids Res. 2006; 35(2):e9. PMC: 1802632. DOI: 10.1093/nar/gkl979. View

16.

Bartek J, Lukas J . Pathways governing G1/S transition and their response to DNA damage. FEBS Lett. 2001; 490(3):117-22. DOI: 10.1016/s0014-5793(01)02114-7. View

17.

Xie K, Doles J, Hemann M, Walker G . Error-prone translesion synthesis mediates acquired chemoresistance. Proc Natl Acad Sci U S A. 2010; 107(48):20792-7. PMC: 2996453. DOI: 10.1073/pnas.1011412107. View

18.

Helleday T, Petermann E, Lundin C, Hodgson B, Sharma R . DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008; 8(3):193-204. DOI: 10.1038/nrc2342. View

19.

Lieber M . The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem. 2010; 79:181-211. PMC: 3079308. DOI: 10.1146/annurev.biochem.052308.093131. View

20.

Lundholm L, Haag P, Zong D, Juntti T, Mork B, Lewensohn R . Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest. Cell Death Dis. 2013; 4:e478. PMC: 3563998. DOI: 10.1038/cddis.2012.211. View